ArticleThrombosis and haemostasis2018
Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients.
Article in Thrombosis and haemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patient values and preferences regarding VTE disease: a systematic review to inform American Society of Hematology guidelines.Blood advances · 2020Pooled it
- Role of PCSK9 inhibitors in venous thromboembolism: current evidence and unmet clinical needs.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- Impact of the VTE-PREDICT calculator on clinicians' decision making in fictional patients with venous thromboembolism: a randomized controlled trial.Research and practice in thrombosis and haemostasis · 2024Article
- Qualitative experiences, values, and decisional needs of patients with unprovoked venous thromboembolism who suffer bleeding-"This pill will keep you alive tonight".Research and practice in thrombosis and haemostasis · 2024Article
- Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2022Article
- Long-Term Management of Pulmonary Embolism: A Review of Consequences, Treatment, and Rehabilitation.Journal of clinical medicine · 2022Review
- The relationship between self-efficacy and treatment satisfaction among patients with anticoagulant therapy: a cross-sectional study from a developing country.Thrombosis journal · 2022Article
- Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis.Research and practice in thrombosis and haemostasis · 2021Article
- Patient Characteristics and Preferences Regarding Anticoagulant Treatment in Venous Thromboembolic Disease.Frontiers in cardiovascular medicine · 2021Article
- An international survey of clinicians regarding their management of venous thromboembolism following the initial 3-6 months of anticoagulation.Journal of thrombosis and thrombolysis · 2021Article
- Long-Term Association of Venous Thromboembolism With Frailty, Physical Functioning, and Quality of Life: The Atherosclerosis Risk in Communities Study.Journal of the American Heart Association · 2020Article
- Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns.Journal of thrombosis and haemostasis : JTH · 2020Article
- Assessing patient preferences for switching from warfarin to direct oral anticoagulants.Journal of thrombosis and thrombolysis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWarfarin and direct oral anticoagulants (DOACs) are used for the initial treatment and secondary prevention of venous thromboembolism (VTE), and have similar efficacy. Patient concerns and preferences are important considerations when selecting an anticoagulant, yet these are not well studied.
methodsVTE patients (
resultsPatients were 83% females and on average (±standard deviation [SD]) 45.7 ± 13.1 years; 65% self-reported warfarin as their initial VTE treatment and 35% a DOAC. Proportions reporting being extremely concerned about the following outcomes were as follows: recurrent VTE 33%, major bleeding 21%, moderate bleeding 16% and all-cause death 29%. When asked about oral anticoagulant characteristics, patients strongly preferred anticoagulants that are reversible (53%), and for which blood drug levels can be monitored (30%). Lower proportions agreed with statements that regular blood testing is inconvenient (18%), that they are comfortable using the newest drug versus an established drug (15%) and that it is difficult to change their diet to accommodate their anticoagulant (17%). In multivariable-adjusted models, patients tended to have had as their initial treatment, and to currently be taking, the oral anticoagulant option they personally preferred. DISCUSSION: Patients held the greatest concern for recurrent VTE and mortality, regardless of which treatment they were prescribed. Potential weaknesses of warfarin (e.g., dietary restrictions, regular monitoring) were generally not considered onerous, while warfarin's advantages (e.g., ability to monitor) were viewed favourably.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.